Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 41 entries
Sorted by: Best Match Show Resources per page
Bone Mineral Density after Weight Gain in 160 Patients with Anorexia Nervosa.

Frontiers in nutrition

Achamrah N, Coëffier M, Jésus P, Charles J, Rimbert A, Déchelotte P, Grigioni S.
PMID: 29034241
Front Nutr. 2017 Sep 29;4:46. doi: 10.3389/fnut.2017.00046. eCollection 2017.

Low bone mineral density (BMD) is a frequent complication in anorexia nervosa (AN). There are controversial points of views regarding the restoration of bone mineralization after recovery in AN. We aimed to assess changes of BMD at 3 years...

Cite
Achamrah N, Coëffier M, Jésus P, et al. Bone Mineral Density after Weight Gain in 160 Patients with Anorexia Nervosa. Front Nutr. 2017;4:46doi: 10.3389/fnut.2017.00046.
Achamrah, N., Coëffier, M., Jésus, P., Charles, J., Rimbert, A., Déchelotte, P., & Grigioni, S. (2017). Bone Mineral Density after Weight Gain in 160 Patients with Anorexia Nervosa. Frontiers in nutrition, 446. https://doi.org/10.3389/fnut.2017.00046
Achamrah, Najate, et al. "Bone Mineral Density after Weight Gain in 160 Patients with Anorexia Nervosa." Frontiers in nutrition vol. 4 (2017): 46. doi: https://doi.org/10.3389/fnut.2017.00046
Achamrah N, Coëffier M, Jésus P, Charles J, Rimbert A, Déchelotte P, Grigioni S. Bone Mineral Density after Weight Gain in 160 Patients with Anorexia Nervosa. Front Nutr. 2017 Sep 29;4:46. doi: 10.3389/fnut.2017.00046. eCollection 2017. PMID: 29034241; PMCID: PMC5626930.
Copy Download .nbib Format: NLM
Synovitis and tenosynovitis of the hands and wrists in patients with SSc: The need for a consensus definition of sclerosing tenosynovitis.

Seminars in arthritis and rheumatism

Caillault L, Droitcourt C, Robin F, Tas M, Coiffier G, Lescoat A.
PMID: 34493395
Semin Arthritis Rheum. 2021 Aug 20; doi: 10.1016/j.semarthrit.2021.08.009. Epub 2021 Aug 20.

No abstract available.

Cite
Caillault L, Droitcourt C, Robin F, et al. Synovitis and tenosynovitis of the hands and wrists in patients with SSc: The need for a consensus definition of sclerosing tenosynovitis. Semin Arthritis Rheum. 2021;doi: 10.1016/j.semarthrit.2021.08.009.
Caillault, L., Droitcourt, C., Robin, F., Tas, M., Coiffier, G., & Lescoat, A. (2021). Synovitis and tenosynovitis of the hands and wrists in patients with SSc: The need for a consensus definition of sclerosing tenosynovitis. Seminars in arthritis and rheumatism, . https://doi.org/10.1016/j.semarthrit.2021.08.009
Caillault, Leïla, et al. "Synovitis and tenosynovitis of the hands and wrists in patients with SSc: The need for a consensus definition of sclerosing tenosynovitis." Seminars in arthritis and rheumatism vol. (2021). doi: https://doi.org/10.1016/j.semarthrit.2021.08.009
Caillault L, Droitcourt C, Robin F, Tas M, Coiffier G, Lescoat A. Synovitis and tenosynovitis of the hands and wrists in patients with SSc: The need for a consensus definition of sclerosing tenosynovitis. Semin Arthritis Rheum. 2021 Aug 20; doi: 10.1016/j.semarthrit.2021.08.009. Epub 2021 Aug 20. PMID: 34493395.
Copy Download .nbib Format: NLM
Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly.

Seminars in oncology

Coiffier B.
PMID: 28140217
Semin Oncol. 2003 Feb;30(1):21-27. doi: 10.1053/sonc.2003.50021.

Rituximab is an anti-CD20 chimeric monoclonal antibody that has shown substantial activity in indolent non-Hodgkin's lymphoma (NHL). Recent data indicate that the clinical benefits achieved in the treatment of indolent NHL are mirrored in aggressive NHL. Diffuse large B-cell...

Cite
Coiffier B. Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly. Semin Oncol. 2003;30(1):21-27doi: 10.1053/sonc.2003.50021.
Coiffier, B. (2003). Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly. Seminars in oncology, 30(1), 21-27. https://doi.org/10.1053/sonc.2003.50021
Coiffier, Bertrand. "Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly." Seminars in oncology vol. 30,1 (2003): 21-27. doi: https://doi.org/10.1053/sonc.2003.50021
Coiffier B. Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly. Semin Oncol. 2003 Feb;30(1):21-27. doi: 10.1053/sonc.2003.50021. PMID: 28140217.
Copy Download .nbib Format: NLM
Research on Biosimilars: pivotal trials and principles.

The Lancet. Haematology

Jurczak W, Vulto AG, Amersdorffer J, Kim WS, Coiffier B.
PMID: 28863801
Lancet Haematol. 2017 Sep;4(9):e409-e410. doi: 10.1016/S2352-3026(17)30152-7.

No abstract available.

Cite
Jurczak W, Vulto AG, Amersdorffer J, et al. Research on Biosimilars: pivotal trials and principles. Lancet Haematol. 2017;4(9):e409-e410doi: 10.1016/S2352-3026(17)30152-7.
Jurczak, W., Vulto, A. G., Amersdorffer, J., Kim, W. S., & Coiffier, B. (2017). Research on Biosimilars: pivotal trials and principles. The Lancet. Haematology, 4(9), e409-e410. https://doi.org/10.1016/S2352-3026(17)30152-7
Jurczak, Wojciech, et al. "Research on Biosimilars: pivotal trials and principles." The Lancet. Haematology vol. 4,9 (2017): e409-e410. doi: https://doi.org/10.1016/S2352-3026(17)30152-7
Jurczak W, Vulto AG, Amersdorffer J, Kim WS, Coiffier B. Research on Biosimilars: pivotal trials and principles. Lancet Haematol. 2017 Sep;4(9):e409-e410. doi: 10.1016/S2352-3026(17)30152-7. PMID: 28863801.
Copy Download .nbib Format: NLM
Preparing for a new generation of biologic therapies: understanding the development and potential of biosimilar cancer therapeutics.

Future oncology (London, England)

Coiffier B.
PMID: 28482698
Future Oncol. 2017 May;13(15):1-3. doi: 10.2217/fon-2017-0157.

No abstract available.

Cite
Coiffier B. Preparing for a new generation of biologic therapies: understanding the development and potential of biosimilar cancer therapeutics. Future Oncol. 2017;13(15):1-3doi: 10.2217/fon-2017-0157.
Coiffier, B. (2017). Preparing for a new generation of biologic therapies: understanding the development and potential of biosimilar cancer therapeutics. Future oncology (London, England), 13(15), 1-3. https://doi.org/10.2217/fon-2017-0157
Coiffier, Bertrand. "Preparing for a new generation of biologic therapies: understanding the development and potential of biosimilar cancer therapeutics." Future oncology (London, England) vol. 13,15 (2017): 1-3. doi: https://doi.org/10.2217/fon-2017-0157
Coiffier B. Preparing for a new generation of biologic therapies: understanding the development and potential of biosimilar cancer therapeutics. Future Oncol. 2017 May;13(15):1-3. doi: 10.2217/fon-2017-0157. PMID: 28482698.
Copy Download .nbib Format: NLM
Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis.

Experimental hematology & oncology

Hess G, Coiffier B, Crump M, Gisselbrecht C, Offner F, Romaguera J, Kang L, Moran PJ.
PMID: 25938001
Exp Hematol Oncol. 2015 Apr 11;4:11. doi: 10.1186/s40164-015-0006-1. eCollection 2015.

BACKGROUND: Temsirolimus, a selective inhibitor of the mammalian target of rapamycin, has demonstrated clinical benefit versus investigator's choice (INV) of therapy in patients with relapsed/refractory mantle cell lymphoma (MCL).METHODS: This post hoc study retrospectively assigned simplified Mantle Cell Lymphoma...

Cite
Hess G, Coiffier B, Crump M, et al. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. Exp Hematol Oncol. 2015;4:11doi: 10.1186/s40164-015-0006-1.
Hess, G., Coiffier, B., Crump, M., Gisselbrecht, C., Offner, F., Romaguera, J., Kang, L., & Moran, P. J. (2015). Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. Experimental hematology & oncology, 411. https://doi.org/10.1186/s40164-015-0006-1
Hess, Georg, et al. "Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis." Experimental hematology & oncology vol. 4 (2015): 11. doi: https://doi.org/10.1186/s40164-015-0006-1
Hess G, Coiffier B, Crump M, Gisselbrecht C, Offner F, Romaguera J, Kang L, Moran PJ. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. Exp Hematol Oncol. 2015 Apr 11;4:11. doi: 10.1186/s40164-015-0006-1. eCollection 2015. PMID: 25938001; PMCID: PMC4416347.
Copy Download .nbib Format: NLM
Lenalidomide in diffuse large B-cell lymphoma.

Advances in hematology

Thieblemont C, Delfau-Larue MH, Coiffier B.
PMID: 23251161
Adv Hematol. 2012;2012:861060. doi: 10.1155/2012/861060. Epub 2012 Nov 20.

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma (NHL) in adults. Even if the natural history of DLBCL has been improved with the advent of immunochemotherapy, the survival results obtained with current treatment options...

Cite
Thieblemont C, Delfau-Larue MH, Coiffier B. Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol. 2012;2012:861060doi: 10.1155/2012/861060.
Thieblemont, C., Delfau-Larue, M. H., & Coiffier, B. (2012). Lenalidomide in diffuse large B-cell lymphoma. Advances in hematology, 2012861060. https://doi.org/10.1155/2012/861060
Thieblemont, Catherine, et al. "Lenalidomide in diffuse large B-cell lymphoma." Advances in hematology vol. 2012 (2012): 861060. doi: https://doi.org/10.1155/2012/861060
Thieblemont C, Delfau-Larue MH, Coiffier B. Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol. 2012;2012:861060. doi: 10.1155/2012/861060. Epub 2012 Nov 20. PMID: 23251161; PMCID: PMC3508519.
Copy Download .nbib Format: NLM
Validity of Bioimpedance Equations to Evaluate Fat-Free Mass and Muscle Mass in Severely Malnourished Anorectic Patients.

Journal of clinical medicine

Coëffier M, Gâté M, Rimbert A, Petit A, Folope V, Grigioni S, Déchelotte P, Achamrah N.
PMID: 33202580
J Clin Med. 2020 Nov 14;9(11). doi: 10.3390/jcm9113664.

BACKGROUND: Bioelectrical impedance analysis (BIA) is a simple and rapid technique to measure body composition (BC). Validity of BIA in patients with low body mass index (BMI) remains controversial. We assessed the validity of several BIA equations to evaluate...

Cite
Coëffier M, Gâté M, Rimbert A, et al. Validity of Bioimpedance Equations to Evaluate Fat-Free Mass and Muscle Mass in Severely Malnourished Anorectic Patients. J Clin Med. 2020;9(11)doi: 10.3390/jcm9113664.
Coëffier, M., Gâté, M., Rimbert, A., Petit, A., Folope, V., Grigioni, S., Déchelotte, P., & Achamrah, N. (2020). Validity of Bioimpedance Equations to Evaluate Fat-Free Mass and Muscle Mass in Severely Malnourished Anorectic Patients. Journal of clinical medicine, 9(11), . https://doi.org/10.3390/jcm9113664
Coëffier, Moise, et al. "Validity of Bioimpedance Equations to Evaluate Fat-Free Mass and Muscle Mass in Severely Malnourished Anorectic Patients." Journal of clinical medicine vol. 9,11 (2020). doi: https://doi.org/10.3390/jcm9113664
Coëffier M, Gâté M, Rimbert A, Petit A, Folope V, Grigioni S, Déchelotte P, Achamrah N. Validity of Bioimpedance Equations to Evaluate Fat-Free Mass and Muscle Mass in Severely Malnourished Anorectic Patients. J Clin Med. 2020 Nov 14;9(11). doi: 10.3390/jcm9113664. PMID: 33202580; PMCID: PMC7698304.
Copy Download .nbib Format: NLM
Spine immobilization and neurological outcome in vertebral osteomyelitis SPONDIMMO, a prospective multicentric cohort.

Joint bone spine

Le Pluart A, Coiffier G, Darrieutort-Lafitte C, Godot S, Ottaviani S, Henry J, Brochard J, Cormier G, Couderc M, Hoppe E, Mulleman D, Khatchatourian L, Le Thuaut A, Le Goff B, Bart G.
PMID: 34954077
Joint Bone Spine. 2021 Dec 22;89(4):105333. doi: 10.1016/j.jbspin.2021.105333. Epub 2021 Dec 22.

OBJECTIVE: The aim of our study was to describe spine immobilization in a multicentric cohort of vertebral osteomyelitis (VO), and evaluate its association with neurological complications during follow-up.METHODS: We prospectively included patients from 2016 to 2019 in 11 centers....

Cite
Le Pluart A, Coiffier G, Darrieutort-Lafitte C, et al. Spine immobilization and neurological outcome in vertebral osteomyelitis SPONDIMMO, a prospective multicentric cohort. Joint Bone Spine. 2021;89(4):105333doi: 10.1016/j.jbspin.2021.105333.
Le Pluart, A., Coiffier, G., Darrieutort-Lafitte, C., Godot, S., Ottaviani, S., Henry, J., Brochard, J., Cormier, G., Couderc, M., Hoppe, E., Mulleman, D., Khatchatourian, L., Le Thuaut, A., Le Goff, B., & Bart, G. (2021). Spine immobilization and neurological outcome in vertebral osteomyelitis SPONDIMMO, a prospective multicentric cohort. Joint bone spine, 89(4), 105333. https://doi.org/10.1016/j.jbspin.2021.105333
Le Pluart, Adrien, et al. "Spine immobilization and neurological outcome in vertebral osteomyelitis SPONDIMMO, a prospective multicentric cohort." Joint bone spine vol. 89,4 (2021): 105333. doi: https://doi.org/10.1016/j.jbspin.2021.105333
Le Pluart A, Coiffier G, Darrieutort-Lafitte C, Godot S, Ottaviani S, Henry J, Brochard J, Cormier G, Couderc M, Hoppe E, Mulleman D, Khatchatourian L, Le Thuaut A, Le Goff B, Bart G. Spine immobilization and neurological outcome in vertebral osteomyelitis SPONDIMMO, a prospective multicentric cohort. Joint Bone Spine. 2021 Dec 22;89(4):105333. doi: 10.1016/j.jbspin.2021.105333. Epub 2021 Dec 22. PMID: 34954077.
Copy Download .nbib Format: NLM
S100B Blood Level Determination for Early Management of Ski-Related Mild Traumatic Brain Injury: A Pilot Study.

Frontiers in neurology

Kahouadji S, Salamin P, Praz L, Coiffier J, Frochaux V, Durif J, Pereira B, Arlettaz L, Oris C, Sapin V, Bouvier D.
PMID: 32922357
Front Neurol. 2020 Aug 14;11:856. doi: 10.3389/fneur.2020.00856. eCollection 2020.

No abstract available.

Cite
Kahouadji S, Salamin P, Praz L, et al. S100B Blood Level Determination for Early Management of Ski-Related Mild Traumatic Brain Injury: A Pilot Study. Front Neurol. 2020;11:856doi: 10.3389/fneur.2020.00856.
Kahouadji, S., Salamin, P., Praz, L., Coiffier, J., Frochaux, V., Durif, J., Pereira, B., Arlettaz, L., Oris, C., Sapin, V., & Bouvier, D. (2020). S100B Blood Level Determination for Early Management of Ski-Related Mild Traumatic Brain Injury: A Pilot Study. Frontiers in neurology, 11856. https://doi.org/10.3389/fneur.2020.00856
Kahouadji, Samy, et al. "S100B Blood Level Determination for Early Management of Ski-Related Mild Traumatic Brain Injury: A Pilot Study." Frontiers in neurology vol. 11 (2020): 856. doi: https://doi.org/10.3389/fneur.2020.00856
Kahouadji S, Salamin P, Praz L, Coiffier J, Frochaux V, Durif J, Pereira B, Arlettaz L, Oris C, Sapin V, Bouvier D. S100B Blood Level Determination for Early Management of Ski-Related Mild Traumatic Brain Injury: A Pilot Study. Front Neurol. 2020 Aug 14;11:856. doi: 10.3389/fneur.2020.00856. eCollection 2020. PMID: 32922357; PMCID: PMC7456809.
Copy Download .nbib Format: NLM
Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions.

OncoTargets and therapy

Karlin L, Coiffier B.
PMID: 23579927
Onco Targets Ther. 2013 Mar 31;6:289-96. doi: 10.2147/OTT.S42574. Print 2013.

Prognosis of diffuse large B-cell lymphoma (DLBCL) has considerably improved during the last decade, mainly due to the addition of rituximab to chemotherapy. However, a significant proportion of patients still experience primary refractory disease or short-term relapses, conferring poor...

Cite
Karlin L, Coiffier B. Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. Onco Targets Ther. 2013;6:289-96doi: 10.2147/OTT.S42574.
Karlin, L., & Coiffier, B. (2013). Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. OncoTargets and therapy, 6289-96. https://doi.org/10.2147/OTT.S42574
Karlin, Lionel, and Coiffier, Bertrand. "Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions." OncoTargets and therapy vol. 6 (2013): 289-96. doi: https://doi.org/10.2147/OTT.S42574
Karlin L, Coiffier B. Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. Onco Targets Ther. 2013 Mar 31;6:289-96. doi: 10.2147/OTT.S42574. Print 2013. PMID: 23579927; PMCID: PMC3621721.
Copy Download .nbib Format: NLM
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.

Journal of hematology & oncology

Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B.
PMID: 28923081
J Hematol Oncol. 2017 Sep 18;10(1):154. doi: 10.1186/s13045-017-0518-8.

No abstract available.

Cite
Foss F, Horwitz S, Pro B, et al. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2017;10(1):154doi: 10.1186/s13045-017-0518-8.
Foss, F., Horwitz, S., Pro, B., Miles Prince, H., Sokol, L., Balser, B., Wolfson, J., & Coiffier, B. (2017). Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal of hematology & oncology, 10(1), 154. https://doi.org/10.1186/s13045-017-0518-8
Foss, Francine, et al. "Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial." Journal of hematology & oncology vol. 10,1 (2017): 154. doi: https://doi.org/10.1186/s13045-017-0518-8
Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2017 Sep 18;10(1):154. doi: 10.1186/s13045-017-0518-8. PMID: 28923081; PMCID: PMC5603163.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 41 entries